UTIs are the most common bacterial infection that women develop throughout pregnancy. They can arise in different components of the urinary tract, such as the bladder (cystitis), urethra (urethritis) or kidneys (pyelonephritis). Recurrent urinary tract infection (RUTI) refers to ≥2 infections in six months or ≥3 infections in one year.
Interventions used to prevent RUTI in pregnant women can be pharmacological (antibiotics) or non-pharmacological (cranberry products, acupuncture, probiotics and behavioral).
Lactoferrin (lactotransferrin; Lf) is an iron-binding glycoprotein and one of the most important bioactivators in milk and other exocrine secretions such as milk, saliva, tear, and nasal secretions. Several studies have shown that human lactoferrin might have anti- bacterial properties that could work on recurrent urinary tract infections.

AIM OF THE WORK:
The aim of the work was to evaluate on the role of lactoferrin (Lf) in pregnant women with recurrent urinary tract infection as a line ofprevention.

PATIENTS AND METHODS:
This research was conducted on 220 pregnant women between 14-24 weeks gestational age with past history of recurrent urinary tract infection, no associated co-morbidities and a normal urine analysis. In this study, 110 patients were given lactoferrin, another 110 patients were control group which were selected based on randomized controlled method.